Mercados españoles cerrados

Incannex Healthcare Inc. (IXHL)

NasdaqGM - NasdaqGM Precio demorado. Divisa en USD
Añadir a la lista de favoritos
3,3200+0,1700 (+5,40%)
Al cierre: 04:00PM EDT
3,3200 0,00 (0,00%)
Después del cierre: 07:37PM EDT

Incannex Healthcare Inc.

8 Century Circuit
Suite 105 Norwest
Sydney, NSW 2153
Australia
61 4 2570 3805
https://www.incannex.com

Sector(es)Healthcare
SectorDrug Manufacturers - Specialty & Generic
Empleados a tiempo completo

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Mr. Joel Bradley LathamPresident, CEO & Executive Director841,75kN/A1990
Mr. Lekhram Changoer M.Sc.Chief Technical Officer104,09kN/A1967
Mr. Joseph SwanCFO, Treasurer, Controller & SecretaryN/AN/A1992
Dr. Mark BleackleyChief Scientific Officer, Head of Programs & Member of the Advisory BoardN/AN/AN/A
Mr. John Michailidis B.Sc., EMBA, M.A.I.C.D.Chief Executive Officer of IncannexTMN/AN/AN/A
Ms. Rosemarie WalshVP of Clinical Operations & Member of the Advisory BoardN/AN/AN/A
Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Healthcare Inc. was incorporated in 2001 and is based in Sydney, Australia.

Gobierno corporativo

El ISS Governance QualityScore de Incannex Healthcare Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.